GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tempus AI TEM · USD

Health Care · US listing · 🇺🇸 United States

Compare

84.44

+11.03%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tempus AI

From its filings with the US Securities and Exchange Commission

SEC filings

Tempus AI is based in Chicago, Illinois and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker TEM. The SEC classifies its business as computer programming, data processing, etc.. In the fiscal year to 31 December 2025, it reported revenue of $1.27bn and a net loss of $245.0m. At that date it held total assets of $2.27bn and shareholders' equity of $491.3m.

In its own words

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient’s own clinical data, thereby personalizing the results. Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patient’s unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path. The drugs recommended, the clinical trials explored, the care pathways evaluated, and the adverse events considered—all have the potential to be refined and enhanced when test results are connected to a patient’s personal profile, enabling the right patient to be routed to the right therapy at the right time.

To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world.

Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
14 Jun 2024
Employees
3,800
Website
tempus.com ↗
Head office
600 WEST CHICAGO AVENUE, CHICAGO, IL, 60654
Incorporated in
NV
Classification
Services-Computer Programming, Data Processing, Etc.
Filer status
Large accelerated filer

Leadership

Pay as last reported

  • Mr. Eric LefkofskyChief Executive Officer, Director$2,100
  • Mr. James RogersChief Financial Officer$3.3m
  • Mr. Ryan FukushimaChief Operating Officer$5.3m
  • Mr. Erik PhelpsExecutive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
  • Mr. Andrew PolovinExecutive Vice President, General Counsel
  • Mr. Peter BarrisIndependent Director
  • Mr. Eric BelcherIndependent Director
  • Dr. Jennifer DoudnaIndependent Director$75,000
  • Mr. David EpsteinIndependent Director
  • Dr. Wayne FrederickIndependent Director$75,000
  • Mr. Robert GhenchevIndependent Director
  • Dr. Scott GottliebIndependent Director$1.0m

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in Life Sciences Tools & Services sector with 3800 employees.
  • Provides next generation diagnostics using genomics and AI applications.
  • Offers AI platform Next for oncology and cardiology care gap identification.

Weaknesses

  • IPO occurred on 2024-06-14, indicating recent market entry.
  • Company is described as a technology company with unverified product claims.
  • No specific financial metrics or market share data provided.

Opportunities

  • Growth potential in personalized medicine through data analytics.
  • Expansion of AI applications in healthcare diagnostics.
  • Leveraging genomics and AI for broader disease area coverage.

Threats

  • Untrusted source description may lead to inaccurate market positioning.
  • Recent IPO could face volatility in stock performance.
  • Competition in AI-driven healthcare diagnostics sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.